Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal
Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals. This program came from a $950 million acquisition in 2019 that marked Vertex’s entry into type 1 diabetes. The post Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal appeared first on MedCity News.
Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals. This program came from a $950 million acquisition in 2019 that marked Vertex’s entry into type 1 diabetes.
The post Vertex Cell Therapy Misses in the Clinic, But It Has Other Shots on the Type 1 Diabetes Goal appeared first on MedCity News.
